Open AccessEngineering-enhanced CAR T cells for improved cancer therapy
Author(s) -
Michael C. Milone,
Jie Xu,
SaiJuan Chen,
McKensie Collins,
Jianfeng Zhou,
Daniel J. Powell,
J. Joseph Melenhorst
Publication year - 2021
Publication title -
nature cancer
Language(s) - English
Resource type - Journals
ISSN - 2662-1347
DOI - 10.1038/s43018-021-00241-5
Subject(s) - chimeric antigen receptor , cd19 , cell therapy , car t cell therapy , t cell , antigen , medicine , cell , cancer research , immunotherapy , cancer , immunology , biology , immune system , genetics
Chimeric antigen receptor (CAR) T-cell therapies have evolved from a research tool to a paradigm-shifting therapy with impressive responses in B cell malignancies. This review summarizes the current state of the CAR T-cell field, focusing on CD19- and B cell maturation antigen-directed CAR T-cells, the most developed of the CAR T-cell therapies. We discuss the many challenges to CAR-T therapeutic success and innovations in CAR design and T-cell engineering aimed at extending this therapeutic platform beyond hematologic malignancies.